font size
Sign in
SAN FRANCISCO, CA-September 2, 2014-M&A activity propelled 2014 into the record books with the announcement of Roche's planned $8.3 billion acquisition of Intermune, the developer of a drug to treat a fatal and unexplained scarring of the lung. The agreement pushed life sciences M&A activity through the first eight months of 2014 to a record $195.7 billion, compared to the previous record of $189.7 billion for all of 2009 for therapeutics, tools, diagnostics, and digital health companies, according to Burrill Media. Read More
Todays Stories
Podcast Therapeutic Vaccine for Parkinson's Disease Shows Early Promise

Kuldip Dave, director of research programs for the Michael J. Fox Foundation, discusses encouraging early-stage results for Affiris' experimental therapeutic vaccine for Parkinson's, what the results tell us, and why alpha-synuclein may be a compelling target in the fight against Parkinson’s disease.

By the numbers Pharmas Tap Academia for Drug Discovery



Non-traditional partnering deals have become the norm over the past few years as Big Pharma has shifted its resources away from internal R&D to outsourcing innovation. Such was the case over the past week as Bristol-Myers Squibb and Astellas Pharma partnered to access biopharmaceutical innovation coming out of academia and research institutes.